Celularity Inc
Celularity Inc. (NASDAQ: CELU) is a cellular and regenerative medicine company focused on developing off-the-shelf allogeneic cellular therapies and advanced biomaterial products derived from postpartum human placenta. The company operates through two primary business segments: cellular therapy development and… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Celularity Inc does
In the company’s own words
Celularity Inc. (NASDAQ: CELU) is a cellular and regenerative medicine company focused on developing off-the-shelf allogeneic cellular therapies and advanced biomaterial products derived from postpartum human placenta. The company operates through two primary business segments: cellular therapy development and advanced biomaterials commercialization.
The company's core platform, Celularity IMPACT, represents a fully integrated end-to-end manufacturing process that sources postpartum placentas from informed consent donors and processes them into cryopreserved cellular therapy products. The platform leverages placental-derived cells' unique biological advantages, including greater stemness, immunological naïveté, and superior proliferation capacity compared to adult-derived cells. Celularity develops two primary allogeneic cell types: natural killer cells and mesenchymal-like allogeneic stem cells, with cenplacel-L representing a lead candidate that has demonstrated encouraging clinical data in Phase 1 and Phase 2 studies across multiple indications including Crohn's disease, multiple sclerosis, and diabetic foot ulcers.
The advanced biomaterials segment commercializes off-the-shelf placental-derived products including Biovance and Biovance 3L, decellularized human amniotic membrane allografts for soft tissue repair; Interfyl, a connective tissue matrix for soft tissue deficits; CentaFlex, a placental matrix derived from umbilical cord; and Rebound, a full-thickness extracellular matrix for wound coverage. The company also operates a biobanking service providing cryogenic preservation of umbilical cord blood and placental-derived cells for expectant parents.
Celularity maintains a 147,215 square foot purpose-built cGMP-compliant manufacturing facility in Florham Park, New Jersey, featuring nine Grade C and six Grade D manufacturing suites for commercial production. The company generates additional revenue through contract manufacturing and development services leveraging its cellular therapy expertise and manufacturing capacity. The company's intellectual property portfolio protects its platform technologies, manufacturing processes, and therapeutic candidates through both company-owned and licensed patents across multiple jurisdictions, with orphan drug designation granted for certain candidates targeting rare diseases.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- FLORHAM PARK, NJ
- Fiscal year end
- December
- CIK
- 1752828
- SIC
- 2834
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Celularity Inc — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Celularity Inc’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Celularity Inc and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Celularity Inc's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Celularity Inc's last four quarterly filings that the numbers alone won't show?”